IDHIFA is a physician endorsed medication used to treat individuals with acute myeloid leukaemia (AML) with an isocitrate hydrogenase-2 (IDH2) transformation whose sickness has returned or has not enhanced after past treatment(s). It isn’t known whether IDHIFA is protected and powerful in children.
IDHIFA is shown for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-2 (IDH2) transformation as recognized by an FDA-approved test.
- Bone pain
- Shortness of breath
- Swelling of arms and legs
- Swelling around the neck, groin, or underarm area
- Fast weight gain (greater than 10 pounds within a week)
If you develop any of those symptoms of differentiation syndrome, your health care supplier could begin you on drugs taken orally or given through a vein (intravenous) known as corticosteroids and should monitor you within the hospital.